By these arrangements, each of the two arms of the antibody includes one light chain and one heavy chain, with the variable regions at the tips of the Y arms defining antigen specificity.

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

Under the collaboration agreement, the parties will combine Harbour BioMed's industry-leading technology platform, proprietary dataset and extensive expertise in antibody development with Insilico's ...

More information: Bo Shi et al, Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in ...

Ono Pharmaceutical has entered a partnership agreement with Epsilon Molecular Engineering (EME) to advance the drug discovery of the variable heavy domain of heavy chain (VHH) antibodies to ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

The HCAb Harbour Mice® platform is revolutionizing antibody development by producing unique heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering ...

Alloy Therapeutics Inc., a biotechnology ecosystem company, has joined forces with Pfizer Inc., to develop a new platform ...